Rituximab treatment for autoimmune limbic encephalitis in an institutional cohort

Neurology

Volumn 86, Issue 18, 2016, Pages 1683-1691

  Lee, Woo Jin ^a   Lee, Soon Tae ^a,b   Byun, Jung Ick ^a,b,c   Sunwoo, Jun Sang ^a,b,d   Kim, Tae Joon ^a,b   Lim, Jung Ah ^a,b   Moon, Jangsup ^a,b   Lee, Han Sang ^a,b   Shin, Yong Won ^a,b   Lee, Keon Joo ^a,b   Kim, Soyun ^a   Jung, Keun Hwa ^a,b   Jung, Ki Young ^a,b   Chu, Kon ^a,b   Lee, Sang Kun ^a,b  

^a Seoul National University Hospital   (South Korea)

^b Seoul National University   (South Korea)

^c Kyung Hee University College of Medicine   (South Korea)

^d Soonchunhyang University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; RITUXIMAB; IMMUNOLOGIC FACTOR;

ADOLESCENT; ADULT; AGED; ARTICLE; AUTOIMMUNE DISEASE; AUTOIMMUNE LIMBIC ENCEPHALITIS; BEHAVIOR; COGNITION; COHORT ANALYSIS; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; FEMALE; FOLLOW UP; HEART PALPITATION; HUMAN; IMMUNOTHERAPY; INFUSION RELATED REACTION; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MULTIPLE CYCLE TREATMENT; PARANEOPLASTIC NEUROPATHY; PNEUMONIA; PRIORITY JOURNAL; RANKIN SCALE; RASH; STEROID THERAPY; TREATMENT OUTCOME; AUTOIMMUNE DISEASES; BLOOD; CEREBROSPINAL FLUID; IMMUNOLOGY; LIMBIC ENCEPHALITIS; MIDDLE AGED; PROSPECTIVE STUDY; PSYCHOLOGY; REGISTER; RETREATMENT; SEVERITY OF ILLNESS INDEX; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AUTOANTIBODIES; AUTOIMMUNE DISEASES; FOLLOW-UP STUDIES; HUMANS; IMMUNOLOGIC FACTORS; LIMBIC ENCEPHALITIS; MIDDLE AGED; PROSPECTIVE STUDIES; REGISTRIES; RETREATMENT; RITUXIMAB; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84966508579     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0000000000002635     Document Type: Article

References (33)

1. Graus F, Saiz A, Dalmau J. Antibodies and neuronal autoimmune disorders of the CNS. J Neurol 2010; 257: 509-517
2. Armangue T, Leypoldt F, Dalmau J. Autoimmune encephalitis as differential diagnosis of infectious encephalitis. Curr Opin Neurol 2014; 27: 361-368
3. Zuliani L, Graus F, Giometto B, Bien C, Vincent A. Central nervous system neuronal surface antibody associated syndromes: review and guidelines for recognition. J Neurol Neurosurg Psychiatry 2012; 83: 638-645
4. Lancaster E, Martinez-Hernandez E, Dalmau J. Encephalitis and antibodies to synaptic and neuronal cell surface proteins. Neurology 2011; 77: 179-189
5. Tüzün E, Dalmau J. Limbic encephalitis and Variants: classification, diagnosis and treatment. Neurologist 2007; 13: 261-271
6. Rosenfeld MR, Titulaer MJ, Dalmau J. Paraneoplastic syndromes and autoimmune encephalitis: five new things. Neurol Clin Pract 2012; 2: 215-223
7. Dalmau J, Rosenfeld MR. Paraneoplastic syndromes of the CNS. Lancet Neurol 2008; 7: 327-340
8. Dalmau J, Tüzün E, Wu HY, et al. Paraneoplastic anti-Nmethyl-D-aspartate receptor encephalitis associated with ovarian teratoma. Ann Neurol 2007; 61: 25-36
9. Prüss H, Dalmau J, Harms L, et al. Retrospective analysis of NMDA receptor antibodies in encephalitis of unknown origin. Neurology 2010; 75: 1735-1739
10. Dalakas MC. B cells as therapeutic targets in autoimmune neurological disorders. Nat Clin Pract Neurol 2008; 4: 557-567
11. Kosmidis ML, Dalakas MC. Practical considerations on the use of rituximab in autoimmune neurological disorders. Ther Adv Neurol Disord 2010; 3: 93-105
12. Gürcan HM, Keskin DB, Stern JN, Nitzberg MA, Shekhani H, Ahmed AR. A review of the current use of rituximab in autoimmune diseases. Int Immunopharmacol 2009; 9: 10-25
13. Pescovitz M. Rituximab, an anti-CD20 monoclonal antibody: history and mechanism of action. Am J Transplant 2006; 6: 859-866
14. Kimby E. Tolerability and safety of rituximab (Mab-Thera). Cancer Treat Rev 2005; 31: 456-473
15. Stone JH, Merkel PA, Spiera R, et al. Rituximab Versus cyclophosphamide for ANCA-associated Vasculitis. N Engl J Med 2010; 363: 221-232
16. Geetha D, Specks U, Stone JH, et al. Rituximab Versus cyclophosphamide for ANCA-associated Vasculitis with renal involvement. J Am Soc Nephrol 2015; 26: 976-985
17. Hauser SL, Waubant E, Arnold DL, et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 2008; 358: 676-688
18. Sellner J, Boggild M, Clanet M, et al. EFNS guidelines on diagnosis and management of neuromyelitis optica. Eur J Neurol 2010; 17: 1019-1032
19. Trebst C, Jarius S, Berthele A, et al. Update on the diagnosis and treatment of neuromyelitis optica: recommendations of the Neuromyelitis Optica Study Group (NEMOS). J Neurol 2014; 261: 1-16
20. Titulaer MJ, McCracken L, Gabilondo I, et al. Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study. Lancet Neurol 2013; 12: 157-165
21. Dalmau J, Gleichman AJ, Hughes EG, et al. Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies. Lancet Neurol 2008; 7: 1091-1098
22. Lancaster E, Lai M, Peng X, et al. Antibodies to the GABA B receptor in limbic encephalitis with seizures: case series and characterisation of the antigen. Lancet Neurol 2010; 9: 67-76
23. Kim TJ, Lee ST, Shin JW, et al. Clinical manifestations and outcomes of the treatment of patients with GABA B encephalitis. J Neuroimmunol 2014; 270: 45-50
24. Lim JA, Lee ST, Jung KH, et al. Anti-N-methyl-d-aspartate receptor encephalitis in Korea: clinical features, treatment, and outcome. J Clin Neurol 2014; 10: 157-161
25. Shin YW, Lee ST, Shin JW, et al. VGKC-complex/LGI1-antibody encephalitis: clinical manifestations and response to immunotherapy. J Neuroimmunol 2013; 265: 75-81
26. Sunwoo JS, Lee ST, Byun JI, et al. Clinical manifestations of patients with CASPR2 antibodies. J Neuroimmunol 2015; 281: 17-22
27. Tunkel AR, Glaser CA, Bloch KC, et al. The management of encephalitis: clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis 2008; 47: 303-327
28. Dale RC, Brilot F, Duffy LV, et al. Utility and safety of rituximab in pediatric autoimmune and inflammatory CNS disease. Neurology 2014; 83: 142-150
29. Kim SJ, Lee JW, Jung CW, et al. Weekly rituximab followed by monthly rituximab treatment for steroid-refractory chronic graft-Versus-host disease: results from a prospective, multicenter, phase II study. Haematologica 2010; 95: 1935-1942
30. Common Terminology Criteria for Adverse EVents (CTCAE V4.0). AVailable at: http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE-4.03-2010-06-14-QuickReference-5x7. pdf. Accessed April 1, 2015
31. Hainsworth JD, Litchy S, Shaffer DW, Lackey VL, Grimaldi M, Greco FA. Maximizing therapeutic benefit of rituximab: maintenance therapy Versus re-treatment at progression in patients with indolent non-Hodgkin?s lymphoma: a randomized phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol 2005; 23: 1088-1095
32. Martin F, Lauwerys B, Lefebvre C, Devogelaer JP, Houssiau F. Side-effects of intravenous cyclophosphamide pulse therapy. Lupus 1997; 6: 254-257
33. Irani SR, Bera K, Waters P, et al. N-methyl-D-aspartate antibody encephalitis: temporal progression of clinical and paraclinical observations in a predominantly nonparaneoplastic disorder of both sexes. Brain 2010; 133: 1655-1667